One in 10 clinics in SA will start to hand out a twice-a-year anti-HIV jab as early as February. The country’s medicines ...

By Dickens Okinyi Kenya’s ongoing fight against HIV has entered a new phase with the roll out of Lenacapavir, a groundbreaking long-acting HIV prevention and treatment drug, set to take place in 2026.

The antibody, called 04_A06, blocked 98.5% of more than 300 different HIV strains in lab tests, including many resistant to ...

Zimbabwe has been chosen as one of 10 countries globally to roll out lenacapavir, the world's first twice-yearly injectable ...

The AHF Global Public Health Institute for Latin America and the Caribbean, in collaboration with the National Institute of ...

The southern Africa nation recently met the UNAids 95-95-95 fast-track targets, meaning that 95% of those living with HIV ...

President Cyril Ramaphosa has acknowledged in court papers that article 19 of the controversial Expropriation Act creates a ...

Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential.

Campaigners in Northern Ireland have called for the introduction of a 'game-changing' drug that will prevent HIV. On Friday ...

O AHF Global Public Health Institute para a América Latina e Caribe, em parceria com o Instituto Nacional de Saúde Pública do ...

In response, the South African National Treasury allocated R750 million in emergency funding to prevent service interruptions ...

Zimbabwe is among 10 nations rolling out lenacapavir, a twice-yearly HIV prevention shot. "We are excited to announce that ...